Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $12.63, for a total transaction of $694,650.00. Following the completion of the transaction, the chief executive officer now directly owns 221,017 shares of the company's stock, valued at approximately $2,791,444.71. The trade was a 19.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, May 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.71, for a total value of $699,050.00.
• On Monday, April 21st, Saurabh Saha sold 14,656 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.29, for a total value of $180,122.24.

Centessa Pharmaceuticals Stock Performance

CNTA traded up $0.57 on Monday, reaching $13.00. The company had a trading volume of 942,018 shares, compared to its average volume of 720,778. The stock has a 50-day moving average price of $12.70 and a 200-day moving average price of $14.83. The stock has a market capitalization of $1.74 billion, a PE ratio of -7.18 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $8.46 and a 1 year high of $19.09. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. As a group, research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CNTA. Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price on the stock. Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set an "outperform" rating and a $6.00 target price for the company. Finally, Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $27.89.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Large investors have recently modified their holdings of the company. Osterweis Capital Management Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter worth about $47,000. Ellsworth Advisors LLC purchased a new stake in Centessa Pharmaceuticals during the 1st quarter valued at approximately $703,000. Jane Street Group LLC acquired a new stake in Centessa Pharmaceuticals during the 1st quarter worth approximately $2,176,000. Exome Asset Management LLC lifted its position in Centessa Pharmaceuticals by 3.7% during the 1st quarter. Exome Asset Management LLC now owns 142,744 shares of the company's stock worth $2,053,000 after acquiring an additional 5,028 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Centessa Pharmaceuticals by 52.9% in the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company's stock valued at $8,760,000 after purchasing an additional 210,737 shares during the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.